Free Trial

Hims & Hers Health, Inc. (NYSE:HIMS) Stock Has Average Price Target of $31.53

Hims & Hers Health logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analyst sentiment is mostly neutral: Sixteen analysts give Hims & Hers an average “Hold” rating, with a consensus 12-month price target of $31.53.
  • Quarterly results fell short of expectations: The company reported EPS of $0.03 versus $0.06 expected and revenue of $890.37 million versus $893.13 million expected, although revenue grew 48.6% year over year.
  • The company plans to offer Eli Lilly’s FDA-approved weight-loss drugs, while expanding privacy-related legal action adds risk. Recent reports also flagged subscriber declines and lower EBITDA guidance.
  • Five stocks we like better than Hims & Hers Health.

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) has been given an average recommendation of "Hold" by the sixteen analysts that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating and three have assigned a buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $31.53.

Several equities research analysts have weighed in on the company. Jefferies Financial Group dropped their target price on Hims & Hers Health from $31.00 to $24.00 and set a "hold" rating on the stock in a research report on Tuesday, November 10th. Truist Financial boosted their target price on shares of Hims & Hers Health from $27.00 to $32.00 and gave the company a "hold" rating in a research note on Monday, August 24th. TD Cowen upped their target price on shares of Hims & Hers Health from $25.00 to $30.00 and gave the stock a "hold" rating in a research report on Tuesday, August 11th. Deutsche Bank raised their price target on shares of Hims & Hers Health from $25.00 to $26.00 and gave the company a "hold" rating in a research note on Tuesday, August 11th. Finally, Wall Street Zen raised Hims & Hers Health from a "sell" rating to a "hold" rating in a report on Saturday, August 15th.

Read Our Latest Analysis on Hims & Hers Health

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, COO Michael Chi sold 14,027 shares of the business's stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $28.39, for a total value of $398,226.53. Following the sale, the chief operating officer directly owned 456,660 shares in the company, valued at approximately $12,964,577.40. The trade was a 2.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Soleil Boughton sold 3,462 shares of the business's stock in a transaction that occurred on Wednesday, October 28th. The stock was sold at an average price of $27.60, for a total transaction of $95,551.20. Following the completion of the sale, the insider owned 293,886 shares in the company, valued at $8,111,253.60. The trade was a 1.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 124,517 shares of company stock worth $3,565,145 over the last ninety days. 11.76% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Bank of America Corp DE increased its stake in Hims & Hers Health by 194.4% in the 1st quarter. Bank of America Corp DE now owns 4,357,672 shares of the company's stock worth $90,465,000 after purchasing an additional 2,877,550 shares in the last quarter. Bank of New York Mellon Corp purchased a new stake in Hims & Hers Health during the second quarter valued at about $46,220,000. Bienville Capital Management LLC acquired a new position in shares of Hims & Hers Health in the second quarter worth about $27,242,000. Principal Financial Group Inc. boosted its holdings in shares of Hims & Hers Health by 97.3% in the first quarter. Principal Financial Group Inc. now owns 1,282,266 shares of the company's stock worth $26,620,000 after buying an additional 632,282 shares during the period. Finally, FirstWave Capital Management LLC boosted its holdings in shares of Hims & Hers Health by 30.6% in the second quarter. FirstWave Capital Management LLC now owns 339,978 shares of the company's stock worth $11,787,000 after buying an additional 79,731 shares during the period. Institutional investors own 63.52% of the company's stock.

Key Hims & Hers Health News

Investors following HIMS have been watching these news items:

Hims & Hers Health Price Performance

Shares of HIMS stock opened at $19.73 on Monday. The firm has a fifty day simple moving average of $27.61 and a 200-day simple moving average of $26.70. The company has a market capitalization of $4.60 billion, a PE ratio of -23.77 and a beta of 2.53. Hims & Hers Health has a twelve month low of $13.74 and a twelve month high of $40.99. The company has a current ratio of 0.92, a quick ratio of 0.84 and a debt-to-equity ratio of 3.85.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its earnings results on Monday, November 9th. The company reported $0.03 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.06 by ($0.03). Hims & Hers Health had a negative return on equity of 9.62% and a negative net margin of 6.65%. The business had revenue of $890.37 million for the quarter, compared to analysts' expectations of $893.13 million. During the same period in the previous year, the firm posted $0.06 earnings per share. The firm's revenue was up 48.6% compared to the same quarter last year. Equities research analysts anticipate that Hims & Hers Health will post -0.21 earnings per share for the current fiscal year.

Hims & Hers Health Company Profile

(Get Free Report)

Hims & Hers Health, Inc. operates a consumer-focused telehealth platform that connects patients with licensed healthcare providers and offers access to treatments and wellness products. Its services include online consultations, prescription care and over-the-counter products. The company serves a range of health needs, including hair loss, sexual health, skin care, mental health and weight management. Its platform also offers primary care and other services, with offerings varying by location and individual eligibility.

See Also

Analyst Recommendations for Hims & Hers Health (NYSE:HIMS)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Hims & Hers Health Right Now?

Before you consider Hims & Hers Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hims & Hers Health wasn't on the list.

While Hims & Hers Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines